Avidity Biosciences Publishes Positive DM1 Trial Results in NEJM

Avidity Biosciences (Nasdaq: RNA) announced that the New England Journal of Medicine (NEJM) has published data from its Phase 1/2 MARINA trial of del-desiran. The study focused on treating Myotonic Dystrophy Type 1 (DM1), a rare genetic disorder affecting muscle function. Results demonstrated a 40% mean reduction in DMPK mRNA, alongside significant improvements in muscle strength and patient mobility. Furthermore, del-desiran showed a favorable safety profile, with the majority of adverse events reported as mild or moderate. This publication serves as a major validation for Avidity’s Antibody Oligonucleotide Conjugates (AOCs) platform in treating rare diseases. Investors view this as a significant de-risking event for the company’s clinical pipeline and long-term commercial potential. The positive clinical outcomes are expected to bolster market confidence in the company's specialized RNA therapeutics.